ACE2 and COVID-19: Because inactivated COVID-19 vaccines exhibit reduced efficacy against VOC in humans8,12,17, we further evaluated the immunogenicity of iCoV2 against a panel of VOC using an established surrogate neutralization assay measuring inhibition of binding between human angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2 spike proteins.